Результаты поиска

African Organization for Research and Training in Cancer: position and vision for cancer research on the African Continent.

The African Organization for Research and training in Cancer (AORTIC) bases the following position statements on a critical appraisal of the state on cancer research and cancer care in Africa including information on the availability of data on cancer burden, screening and prevention for cancer in Africa, cancer care personnel, treatment modalities, and access to cancer care.

Совпадение в полном тексте источника
… Thirdly, the number of oncologists and other cancer clinical specialists remains inadequate to deal with the current cancer burden. … The situation doesn’t appear to improve as the projected number of oncologists and other cancer specialists continues to fall short in meeting the requirements to control the growing cancer burden in Africa. …

Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.

Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs of DRMM have not previously been reported. We analyzed detailed medical resource utilization (MRU) costs, drug costs and outcomes for 39 UK patients receiving standard DRMM therapy. Median OS in this cohort was 5.6 months. The mean cost of DRMM treatment plus MRU until death was £23,472 [range: £1,411-£90,262], split between drug costs £11,191 and other resource use costs £12,281. The cost per assumed quality-adjusted li

Bisphosphonate-related osteonecrosis of the jaw: a review of the literature.

Bisphosphonates (BPs) are a class of drugs used to treat osteoporosis and malignant bone metastasis. BPs show high binding capacity to the bone matrix, especially in sites of active bone metabolism. The American Society for Bone and Mineral Research defines BRONJ as "an area of exposed bone in the maxillofacial region that has not healed within 8 weeks after identification by a healthcare provider in a patient who is receiving or has been exposed to a bisphosphonate and has not had radiation therapy to the craniofacial region." Bisphosphonate-related osteonecrosis of the jaw (BRONJ) can advers

Emergency Department Management of Common End-of-Life and Palliative Care Symptoms: Three Cases

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Перспективы пациентов в отношении стоимостных и качественных показателей лечения рака на основе ценностей.

Перспективные перспективы и предпочтения имеют важное значение при установлении качественных и стоимостных показателей для моделей выплат на основе стоимости (ВБП), с тем чтобы обеспечить увязку услуг по лечению раковых заболеваний с учетом интересов пациентов и стимулов в отношении ПВП. Были собраны сведения о моделях оказания помощи на основе стоимости (ВБК) от пациентов с системой " Медикэр " и one В процентах 4 Обычные раковые заболевания (многообразная миелома, мочевой пузырь, лёгкие и простаты), включенные в усовершенствованную онкологическую модель Medicare. Это исследование в

Совпадение в полном тексте источника
… Practice patterns among oncologists participating in the oncology care model after three years. J Cancer Policy. 2021;29:100294. 10.1016/j.jcpo.2021.100294 18. Centers for Medicare & Medicaid Services . Enhancing Oncology Model. … The utility of cost discussions between patients with cancer and oncologists. Am J Manag Care. 2015;21(9):607–615. 36. Lyss A, Kern B, Abrams J, et al. Why EOM participation was extremely low-and how to fix it. Am J Manag Care. 2023;29(Spec. No. 9):SP880–SP882. 10.37765/ajmc.2023.89492 37. …

Cross-Cultural Validation of the COmprehensive Score for Financial Toxicity (COST) Measure in an Australian Sample.

IntroductionThe COmprehensive Score for Financial Toxicity (COST) measure developed in the United States measures the financial impact resulting from cancer and its treatment. This paper reports on an Australian cross-cultural validation of the COST measure.MethodsParticipant eligibility criteria included individuals aged ≥ 18, undergoing or completed primary treatment for cancer. Immediate family members of patients were also eligible for Phase 1. Face and content validity were assessed through concurrent interviews and a brief survey (Phase 1). The subsequent revised version of COST was fiel

Совпадение в полном тексте источника
… In Australia, most oncologists address treatment expenses with fewer than half of their patients, despite recognizing their importance [ 39 ]. … Morton , “ Discussion of Costs and Financial Burden in Clinical Practice: A Survey of Medical Oncologists in Australia ,” PLoS One 17 ( 2022 ): e0273620 . 36269711 10.1371/journal.pone.0273620 PMC9586404 40 Z. Zhu , W. Xing , H. …

Analysis of 2023 World Health Organization cancer Essential Medicines List and concordance with resource-stratified guidelines.

BackgroundThe World Health Organization (WHO) Essential Medicines List (EML) and resource-stratified guidelines both prioritize high-value medicines. We compared the 2023 EML cancer medicines list with global cancer statistics, examined the proportion of EML therapies recommended by resource-stratified guidelines, and identified gaps that merit evaluation by the WHO EML Committee.MethodsWe compared the 2023 EML medicines for adult cancers with cancer incidence and mortality data from GLOBOCAN 2022. We cross-referenced the EML with 2 resource-stratified guidelines (National Comprehensive Cancer

Совпадение в полном тексте источника
… The NCG guidelines are developed by clinicians, mostly oncologists, working in a resource-constrained setting, while the NCCN guidelines are generated predominantly by clinicians from high-income countries. 18 We also recognize that resource-stratified guidelines have not been supported by the WHO, although … Accessed June 20, 2023. https://ascopubs.org/doi/10.1200/JGO.18.00113 6 Fundytus A , Sengar M , Lombe D , et al Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey . …

Radiofrequency Ablation of Painful Spinal Metastasis: A Systematic Review.

OBJECTIVE: To systematically evaluate the effectiveness and safety of radiofrequency ablation (RFA) for managing pain caused by spinal metastases. This review aimed to consolidate evidence on RFA's analgesic efficacy and associated risks to inform clinical practice in palliative cancer care. METHODS: A systematic review adhering to PRISMA guidelines was conducted. Databases were searched for studies evaluating RFA for spinal metastases pain. Inclusion criteria specified: randomized or non-randomized studies (prospective/retrospective); ≥3 adult patients; RFA used alone or combined with other

Совпадение в полном тексте источника
… Managing these complications often requires a complex, multidisciplinary approach involving oncologists, neurosurgeons, radiation oncologists, pain specialists, and rehabilitation professionals. …

Exploring participant perceptions of a virtually supported home exercise program for people with multiple myeloma using a novel eHealth application: a qualitative study.

IntroductionSupervision, tailoring, and flexibility have been proposed as key program elements for delivering successful exercise programs for people with multiple myeloma (MM). However, no studies to date have evaluated the acceptability of an intervention employing these components. The aim of this study was to determine the acceptability of a virtually supported exercise program and eHealth application for people with MM.MethodsA qualitative description approach was used. One-on-one interviews were conducted with participants who completed the exercise program. Content analysis was used to

Emergency department use by patients who received chimeric antigen receptor T cell infusion therapy.

BackgroundChimeric antigen receptor T cell infusion (CAR T) therapy has revolutionized the treatment of hematologic malignancies, but treatment-related toxicities are of concern. Understanding the timing and reasons for which patients present to the emergency department (ED) after CAR T therapy can assist with the early recognition and management of toxicities.MethodsA retrospective observational cohort study was conducted for patients who had undergone CAR T therapy in the past 6 months and visited the ED of The University of Texas MD Anderson Cancer Center between 04/01/2018 and 08/01/2022.

Совпадение в полном тексте источника
… The patients that visit the ED are assessed and treated by the staff in the ED, in consultation with the patient’s oncologist. There is also an ED-run observation unit in the hospital, which serves patients projected to need in-hospital care for less than 2 midnights. … Additionally, patients may also be admitted directly to the hospital by their oncologists, while bypassing the ED. Variables and data collection Thirty-day and 90-day mortality rates for the ED visits were calculated from the time of the index ED presentation to the reported time of death. …

Participation and Influencing Factors in the Decision-Making of Life-Sustaining Treatment: A Focus on Deceased Patients with Hematologic Neoplasms.

PurposeThis study aimed to investigate the involvement of patients who died from hematologic neoplasms in the decision-making process surrounding the withdrawal of life-sustaining treatment (LST).MethodsA total of 255 patients diagnosed with hematologic neoplasms who ultimately died following decisions related to LST during their end-of-life period at a university hospital were included in the study. Data were retrospectively obtained from electronic medical records and analyzed utilizing the chi-square test, independent t-test, and logistic regression.ResultsIn total, 42.0% of patients partic

Совпадение в полном тексте источника
… In a study focusing on patients aged 60 years or older with acute leukemia, it was found that 90% of patients believed they could fully recover from acute leukemia, while hematologic oncologists only estimated a 31% chance of complete recovery [ 4 ]. … Oncologist. 2019;24:247–54. doi: 10.1634/theoncologist.2018-0317. 5. El-Jawahri A, Nelson AM, Gray TF, Lee SJ, LeBlanc TW. Palliative and end-of-life care for patients with hematologic malignancies. J Clin Oncol. 2020;38:944–53. doi: 10.1200/JCO.18.02386. 6. …

Оценка иглоукалывания и аурикулотерапии при борьбе с тошнотой и рвотой, вызванной химиотерапией: экспериментальное исследование.

ЦЕЛЬ: Оценка эффективности иглоукалывания и аурикулотерапии в деле уменьшения тошноты, вызванной химиотерапией, и рвоты у больных раком, по сравнению с антиэметическим протоколом. МЕТОД: Пилотное исследование прагматического two- Клинические испытания с применением огнестрельного оружия: группа иглоукалывания получила системную иглоукалывание, аурикулотерапию и антиеметический протокол; контрольная группа использовала антиеметический протокол. Образец состоял из: 42 больные раком желудочно-кишечной системы или множественной миеломой. Результаты были оценены с помощью инструмента химиотерапии п

A cross-sectional study on Chinese oncology nurses' knowledge of bone health among cancer patients.

OBJECTIVE: To understand the knowledge status, obstacle factors, and management confidence of oncology nurses on the bone health of cancer patients, and in addition to provide reference for establishing bone health knowledge training system for oncology nurses and guiding them to manage bone health of cancer patients. METHODS: A total of 602 nurses engaged in oncology nursing in 6 hospitals in Hebei Province were selected by cluster sampling, and an online anonymous survey was conducted by sending questionnaires to oncology nurses from the Hebei Cancer Prevention and Control Association. The

Совпадение в полном тексте источника
… metastases A total of 84.72% of oncology nurses believed that the lack of relevant knowledge training was the main obstacle, 72.26% believed that the main factor was a lack of time to accompany patients, 79.40% believed that it is the lack of care guidelines for bone health management developed by oncologists … The main obstacles to optimal management of patients with bone metastases and CTIBL patients are lack of relevant knowledge and training, lack of time to accompany patients, and lack of care guidelines for bone health management developed by oncologists. …

Skip pattern approach toward the early access of innovative anticancer drugs.

BackgroundWith the rapid development of innovative anticancer treatments, the optimization of tools able to accelerate the access of new drugs to the market by the regulatory authority is a major issue. The aim of the project was to propose a reliable methodological pathway for the assessment of clinical value of new therapeutic innovative options, to objectively identify drugs which deserve early access (EA) priority for solid and possibly in other cancer scenarios, such as the hematological ones.Materials and methodsAfter a comprehensive review of the European Public Assessment Report of 21

Совпадение в полном тексте источника
… The latter consisted of nine medical oncologists (AA, ABi, CCa, MD, AI, RL, GP, DS, MV), four hematologists (CCr, GG, FL, GS) and one pharmacist (ABo) who evaluated the drugs/indications considered. … Oncologists or hematologists evaluated in two independent review sections, the EPAR documentation or individual articles (when available) and expressed their judgment through an ad hoc designed case report form. …

Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.

ImportanceIn many health systems, access to off-label drug use is controlled through reimbursement restrictions by health insurers, especially for expensive cancer drugs.ObjectiveTo determine whether evidence from randomized clinical trials is associated with reimbursement decisions for requested off-label use of anticancer drugs in the Swiss health system.Design, setting, and participantsThis cross-sectional study used reimbursement requests from routinely collected health records of 5809 patients with drug treatment for cancer between January 2015 and July 2018 in 3 major cancer centers, cov

Совпадение в полном тексте источника
… Thus, most patients with cancer in Switzerland had access to off-label use, but the decision-making process by the health insurer was not transparent to the requesting oncologist or hematologist and not evidence-based. … Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol. 2013;31(9):1134-1139. doi: 10.1200/JCO.2012.42.7252 4. Joerger M, Schaer-Thuer C, Koeberle D, et al. …

Solitary osseous plasmacytomas in dogs: 13 cases (2004-2019).

ObjectivesTo further characterise solitary osseous plasmacytoma in dogs, an extremely rare disease. To describe diagnosis, disease progression and treatment outcomes in dogs with solitary osseous plasmacytoma.Materials and methodsRetrospective review of dogs with solitary osseous plasmacytomas that were diagnosed and treated at a single institution from 2005 to 2019. Kaplan-Meier single group survival analysis was used to estimate median survival time and progression-free interval.ResultsThirteen dogs met the inclusion criteria for the study, and of those, 11 were treated. The median age at di

Recursive Partitioning Analysis for Local Control Achieved With Stereotactic Body Radiation Therapy for the Liver, Spine, or Lymph Nodes.

PurposeThis study aims to develop a local control risk stratification using recursive partitioning analysis (RPA) for patients receiving stereotactic body radiation therapy (SBRT) for metastatic cancer.Methods and materialsA single institutional database of 397 SBRT treatments to the liver, spine, and lymph nodes was constructed. All treatments required imaging follow-up to assess for local control. Cox proportional hazards analysis was implemented before the decision tree analysis. The data were split into training (70%), validation (10%), and testing (20%) sets for RPA to optimize the traini

Совпадение в полном тексте источника
… Clinical follow-up was variable, including radiation oncologists, medical oncologists, pulmonologists, neurosurgeons, and others. …

Effect of a Mobile App for the Pharmacotherapeutic Follow-Up of Patients With Cancer on Their Health Outcomes: Quasi-Experimental Study.

BackgroundOral antineoplastic agents (OAAs) have revolutionized cancer management. However, they have been reported with adverse side effects and drug-drug interactions. Moreover, patient adherence to OAA treatment is critical. Mobile apps can enable remote and real-time pharmacotherapeutic monitoring of patients, while also promoting patient autonomy in their health care.ObjectiveThe primary objective was to analyze the effect of using a mobile app for the follow-up of patients with oncohematological malignancies undergoing treatment with OAAs on their health outcomes. The secondary objective

Совпадение в полном тексте источника
… Pharmacotherapeutic Follow-Up Via the App Between January 2016 and May 2017, a team of hospital pharmacists, oncologists, hematologists, and computer scientists designed the e-OncoSalud app [ 2 ]. e-OncoSalud is a custom-designed app that promotes pharmacotherapeutic follow-up at home and the safety … In another study that analyzed an app for the follow-up of patients with lung cancer, registration and follow-up of symptoms and subsequent management by the oncologist improved the quality of life [ 20 ]. …

Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.

ObjectivesValue-based pricing of oncology drugs provides a best estimate for the price of a drug, as it relates to the benefits it provides for individual patients. To date, the impact of value-based pricing to reference cost-effectiveness thresholds (λ) on individual and population-level health benefits remains uncharacterized. The current study examined the potential benefits of value-based pricing by quantifying the incremental net health benefit (INHB) of publicly funded oncology drugs, if funding occurred at manufacturer-submitted price without value-based pricing.MethodsPan-Canadian Onco

Совпадение в полном тексте источника
… Oncologist. 2009;15:24‐31. 38. Lizan L, Dilla T, Paz S, et al. Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population. Patient Prefer Adherence. 2016;10:1‐7. 39. Bertram MY, Lauer JA, De Joncheere K, et al. …

Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia.

IntroductionEvidence on long-term effectiveness and cost effectiveness of treatment sequences for multiple myeloma (MM) is sparse. We used published data and country-specific data to assess the cost effectiveness of four-line treatment sequences for elderly transplant-ineligible patients with MM in Serbia.MethodWe developed a Markov cohort model to compare long-term effectiveness and cost effectiveness of five sequential MM treatment alternatives from the perspective of the national healthcare provider. Effectiveness parameters on progression, mortality and adverse events were extracted from p